Ellison temporarily surpassed Musk to become the world's richest! What additional investment opportunities are hidden behind the soaring share price of Oracle?
The interest rate cut cycle is approaching in 2025! The U.S. biotechnology sector is expected to benefit; how can investors seize the opportunity?
Every September, the Wall Street Board raises the alarm: The market is aware that the performance of US stocks is generally weak in September, which is now known as the September slump. Historical Data shows that September is indeed one of the least significant US equity indices.
Wall Street's “God of Fortune” Tom Lee predicts this year's “September spell” will be broken as Fed rate cuts will help U.S. stocks rise. Tom Lee further looks back at the same years in history for the same period on two occasions:
In 1998, the Fed cut interest rates to ease the financial crisis, not only calmed market panic, but opened a long bull market across the millennium, with value stocks climbing in tandem with growth stocks.
In 2024, the Fed reversed course after a prolonged tightening policy, and the markets bounced back, and a concentrated burst at the end of the year.
Notably, after disappointing August non-farm employment data last Friday and the announcement of the highest unemployment rate since 2021, investors completely digested the Fed's expectation of a 25 basis point cut next week, and even a weak 10% probability of a 50 basis point cut outright.
The IMF's MMF monetary policy will move towards broadening, sensible investors are looking forward to the next step. What Assets are looking forward to investment opportunities in the Global Monetary Policy direction, interest rates are welcome to fall, and the timing of a new cycle of volatility expansion is coming?
The US Medical Industry may be one of the answers.
Medical healthcare stocks are looking forward to a strong upswing from the recent Fed decline. Previous ArticlesMaster of Prosperity! Industries Desire to Dive Into Big Winner”In other words, the Industry showed the greatest benefits in each of the downturns.
Biotechnology Industry to Grow Higher in Forecasts of Reduction
Since the low on April 9, $SPDR S&P Biotech ETF(XBI.US)$ Aggregated rebound of nearly 37%, winning $S&P 500 Index(.SPX.US)$ A 30% increase in the same period.
Looking ahead to the full year, AI Medical Shares $Tempus AI(TEM.US)$ Cumulative increase of more than 130%, global biopharmaceuticals $Insmed(INSM.US)$ Increased by more than 110%, $BridgeBio Pharma(BBIO.US)$ 、 $Alnylam Pharmaceuticals(ALNY.US)$ It has risen by over 90%. $BeiGene(ONC.US)$ Accumulated by more than 85%.
Taking this into account, the US equity market has a lot of Biotechnology-related ETFs to investors, including $ARK Genomic Revolution ETF(ARKG.US)$ 、 $iShares Biotechnology ETF(IBB.US)$ 、 $First Trust Exchange Traded Fund Nyse Arca Biotechnology Index Fund(FBT.US)$ 、 $VanEck Biotech ETF(BBH.US)$ 、 $SPDR S&P Biotech ETF(XBI.US)$ These ETFs have gained between 6% and 8% this year.
How do you define the Biotechnology Industry to reduce the reporting period?
Market people indicate that the current time, or is a good time to publish CNI Biomedicine Index investments—the CNI Biomedicine Index sector has generally performed well during the downturn week.
The CNI Biomedicine Technology Technology Development Week is long, the investment is high, the costs are high, and the outflow of foreign funds is often higher in the previous period. High ROI Companies, Low Risk Investment Yields Higher Returns, Easy Funds Do Not Consent Greater Risks to Invest in Novel Drug Development Assets.
As interest rates recede, the risk of market risks will increase, the financial distress of innovative pharmaceutical companies will decrease, more money will be re-inflow into the Stock Market, Pharmaceutical Markets, Medical Pills Sector will receive more money, More money will be invested in Innovative Medicines Sector, and Innovative Tablet Sectors With good luck.
Other than that, pharmaceutical companies with relatively large and stable cash flow can lose during a downswing week is that stocks need to be sticky, not depending on the economic cycle. Although Multi-Medical Shares are Dividend Stocks, they are also known as repurchases of large-cap stocks, which have been used to absorb the strength of medical stocks during the soft economic period.
